Abstract
Introduction
Following the patent expiries of angiotensin-II receptor blockers Datamonitor
expects antihypertensives sales in the seven major markets to record sales of
$29.5 billion in 2018, a drop of over $6 billion compared to 2008.
Key reasons to purchase this research
- Quantify the future size of the antihypertensives market and identify
opportunities for new products.
- Learn how recent changes related to product expiries will shape the
antihypertensives market.
- Understand the barriers to uptake for novel antihypertensive agents, and
the need for paradigm shift in clinical trial design.
| 
View Cart
